Austedo FDA Approval History
FDA Approved: Yes (First approved April 3, 2017)
Brand name: Austedo
Generic name: deutetrabenazine
Dosage form: Tablets
Previous Name: SD-809
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Huntington's Disease, Tardive Dyskinesia
Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease and the treatment of tardive dyskinesia.
Development timeline for Austedo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.